Announced Tue, 16 Jun · 14:44 IST
Marksans Pharma completes acquisition of QliniQ B.V.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.1%1-day move
₹249.75
prior close
₹247.60
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.1-0.0-0.2+2.1+4.7+3.7+2.7+6.2+3.3+5.7+10.1——
Up moveDown movePending
AI summary
Marksans Pharma has completed the process of acquiring 100% share capital of QliniQ B.V., a Netherlands-based company. This follows the company's earlier communication dated 1st June 2026 regarding the deal. The intimation was made under SEBI Listing Regulations to NSE and BSE. No financial details of the deal were disclosed in this filing.
Likely market impact
Completes a 100% overseas acquisition, expanding the company's global footprint, though deal value remains undisclosed.